Montag A & Associates Inc. Has $637,000 Holdings in Medtronic PLC $MDT

Montag A & Associates Inc. trimmed its holdings in Medtronic PLC (NYSE:MDT) by 9.5% in the 2nd quarter, Holdings Channel reports. The fund owned 7,244 shares of the medical technology company’s stock after selling 761 shares during the quarter. Montag A & Associates Inc.’s holdings in Medtronic were worth $637,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. 1248 Management LLC bought a new position in shares of Medtronic during the 1st quarter worth about $26,000. Twin Tree Management LP bought a new stake in shares of Medtronic in the first quarter valued at about $29,000. Activest Wealth Management grew its position in Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after buying an additional 322 shares in the last quarter. Investment Management Corp VA ADV increased its stake in Medtronic by 144.2% during the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 238 shares during the period. Finally, GFG Capital LLC acquired a new position in Medtronic in the 2nd quarter valued at approximately $36,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

Medtronic stock opened at $95.32 on Wednesday. The firm has a market capitalization of $122.27 billion, a P/E ratio of 26.26, a P/E/G ratio of 2.42 and a beta of 0.77. The stock has a fifty day moving average price of $94.24 and a two-hundred day moving average price of $90.18. Medtronic PLC has a 52-week low of $79.29 and a 52-week high of $99.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were issued a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Analysts Set New Price Targets

Several analysts have recently weighed in on MDT shares. Sanford C. Bernstein reissued an “outperform” rating and set a $98.00 price objective on shares of Medtronic in a report on Friday, October 31st. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research report on Sunday, November 2nd. Stifel Nicolaus boosted their price target on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $102.82.

Insider Activity at Medtronic

In other news, Director William R. Jellison bought 2,500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was bought at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the purchase, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. The trade was a 100.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.